International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 210-218 www.ijprajournal.com ISSN: 2249-7781

An Overview on Analytical Methods Used For the Estimation of Antidiabetic Drugs

Nisha Sanjay Pagar*[1] and Dr. Kiran B. Dhamak[1]
Department of Quality Assurance, Pravara Rural Education Society's College of Pharmacy for Women's, Chincholi, Nashik, MS,India.

Submitted: 01-01-2022 Accepted: 10-01-2022

ABSTRACT

The new FDA measurements address that the normal number of medication filings are expanding each year in the push regions like enemy of malignant growth specialists, hostile to diabetic, anti-toxins, cardio-vascular medications, respiratory medications and so on Sodium glucose co-carrier 2(SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors and biguanides are viable oral enemy of diabetic specialists utilized in treatment of type 2 Diabetes Mellitus. Along these lines, the need to investigate and look at the current scientific and bioanalytical tests utilized for assurance of such medications either single or in mix is significant. Besides, the current audit underlines the most well-known security demonstrating measures to hold any importance with the experts in the space of medication control. This audit helps in understanding the further requirement for the improvement of scientific techniques for the assessment of such medications.

Key-words: Analysis**,** diabetes, drugs, anti diabetic, HPLC

I. INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a worldwide pandemic, as obvious from the worldwide cartographic image of diabetes by the International Diabetes Federation [1]. Diabetes mellitus is an ongoing, moderate, not entirely comprehended metabolic condition mainly portrayed by hyperglycemia. Impeded insulin discharge, protection from tissue activities of insulin, or a mix of both are believed to be the commonest reasons adding to the Pathophysiology of T2DM, a range of sickness initially emerging from tissue insulin obstruction and steadily advancing to a state described by complete loss of secretary action of the beta cells of the pancreas.T2DM is a significant supporter of the exceptionally enormous ascent in the pace of non-transferable illnesses [2-3].

Logical strategy approval guarantees that different HPLC insightful methods will give solid and repeatable outcomes; it is a critical stage in growing new dose structures as it gives data about exactness, linearity, accuracy, discovery, and quantitation limits. As per the ICH rule, "the goal of approval of a logical strategy is to exhibit that it is reasonable for its planned reason." It is presently compulsory during the time spent medication advancement to supply the approval information for the capable specialists. Rules for investigation strategy approval incorporate ICH and USP rules [4, 5].

Analytical methods play an essential role in the adequate fulfillment of product quality attributes. However, the proper quality can only be reached if the analytical method undergoes an appropriate validation process. Analytical validation comprises a formal, systematic, and documented tool that measures the ability of an analytical method to provide reliable, accurate, and reproducible results. In this context, the main regulatory agencies around the world have proposed several guidelines regarding analytical validation, such as the Agência Nacional de Vigilância Sanitária (ANVISA) (2017), World Health Organization (WHO) (2016), European Medicines Agency (EMA) (2016), and Food and Drug Administration FDA (2015). Moreover, the guidelines proposed by the International Council for Harmonization (ICH) serve as a worldwide basis for both regulatory authorities and the pharmaceutical industry. Despite the availability of several guidelines, very often reviewing the scientific literature, analytical validations have been performed with misconception or in an incomplete way. A disregard for the peculiarities related to the analytical technique being adopted, the type and nature of the sample, and the analytical purpose have significantly contributed to

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 210-218 www.ijprajournal.com ISSN: 2249-7781

such mistakes. Another relevant factor that adds to these misunderstandings is the consideration of regulatory guidelines as exhaustive checklists for analytical validation processes. However, once regulatory guidelines have a comprehensive normative character, not only the case-by-case peculiarities will be covered. In this way, the aim of this work is to critically discuss analytical validation by evaluating the concepts and different accomplishments of each analytical performance parameter, as well as their limitations. Thus, we hope to contribute to the critical understanding of analytical validation, demystifying part of the usual concept that regulatory guidelines should be used as a standard and exhaustive checklist. In the pharmaceutical area, different analytical techniques such as infrared and ultraviolet-visible spectrometry, thermal analysis, and chromatography are applied. Since high performance liquid chromatography (HPLC) has been more prominent among pharmaceutical analytical applications.

II. ANALYSIS OF ANTIDIABETIC DRUGS

The different anti-diabetic drugs which are analyzed by RP-HPLC method had been extensively studied as follows for the research purpose

1. An isocratic switched stage elite execution fluid chromatography (RP-HPLC) technique has been produced for fast an concurrent partition and assessment of 3 antidiabetic drugs, specifically, metformin, pioglitazone, and glimepiride, in human plasma inside 3 min. Partition was done on a MAGELLEN 5U C18 (5 µm, 150 mm × 4.60 mm) utilizing a versatile period of MeOH–0.025 M KH2PO4 changed in accordance with pH 3.20 utilizing ortho-phosphoric corrosive (85:15, v/v) at surrounding temperature. The stream rate was 1 mL/min, and the greatest retention was estimated at 235 nm. The maintenance season of metformin, pioglitazone, and glimepiride was noted to be 1.24, 2.32, and 2.77 min, separately, showing an extremely short examination time contrasted with that of other detailed strategies. Additionally, cutoff points of discovery were accounted for to be 0.05, 0.26, and 0.10 µg/mL for metformin, pioglitazone, and glimepiride, separately, showing a serious level of strategy affectability. The strategy was then approved by the FDA rules for the assurance of the three medications clinically in human plasma, specifically, in regards to pharmacokinetic and bioequivalence reproduction considers. [6]
2. Simple, delicate, quick, and exact superior execution fluid chromatographic (HPLC) technique is created and approved for the concurrent assurance of diltiazem, metformin, pioglitazone, and rosiglitazone hydrochloride in unrefined components, their drug details, and human serum. In HPLC, all the above drugs were chromatographed utilizing acetonitrile–methanol–water (30:20:50, v/v, pH 2.59 ± 0.02) as the portable stage at a stream pace of 1.0 mL/min at surrounding temperature. The division is completed on a Hiber, 250-4.6 RP-18 section, outfitted with an UV–vis identifier at 230 nm. All the antidiabetic drugs eluted at various maintenance time and each showed a decent goal from diltiazem. The strategy is effectively applied to drug plans on the grounds that no chromatographic obstructions from the tablet excipients are found. The strategy is viewed as direct, exact, and exact with apt recognition and measurement limit. Appropriateness of the technique for the quantitative assurance of the medications is demonstrated by approval as per the prerequisites set somewhere around International Conference on Harmonization (ICH) rules. The approval results, along with measurable treatment of the information, exhibited the unwavering quality of this strategy. [7]
3. A new RP-HPLC technique for the quantitative assurance of Ertugliflozin and Sitagliptin was created and approved according to ICH rules. The medications were infused into Std Azilent segment (150×4.6, 5 µm), kept up with at surrounding temperature and gushing checked at 240 nm.The portable stage comprised of Buffer (Potassium di hydrogen Ortho Phosphate): Acetonitrile (70:30 V/V). The stream rate was kept up with at 1.0 ml/min. The alignment bend for Ertugliflozin and Sitagliptin were straight from 3.75-22.5µg/ml and 25-150µg/ml separately (r2 for Ertugliflozin = 0.9992,r2 for Sitagliptin = 0.9995). Maintenance time was 3.203min (Ertugliflozin), 2.106min (Sitagliptin). Exactness was in the scope of 99.67-99.90% for the two medications. Accuracy was 0.1% and 0.2% for Ertugliflozin and Sitagliptin,

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 210-218 www.ijprajournal.com ISSN: 2249-7781

LOD and LOQ are 0.43ug/ml and 1.31ug/ml for Ertugliflozin and , 0.74ug/ml and 2.24ug/ml for Sitagliptin. The proposed technique was sufficient, touchy, reproducible, exact and exact for the assurance of Ertugliflozin and Sitagliptin in mass and drug measurement structures. When applied for tablet examine, drug content was inside 99.18.-99.13 % of named content. Constrained corruption studies demonstrated the reasonableness of the strategy for solidness considers. [8]

4. Metformin Hydrochloride and Gemigliptin is blend of Antidiabetic drug in tablet Zemimet SR ® Tablet (25/500 mg), a part Antidiabetic drug, is a new medication created by LG Life sciences for the treatment of Type 2 diabetes. Another touchy and fast HPLC strategy was produced for the assurance of Metformin Hydrochloride and Gemigliptin in drug measurement structures; it was approved by International Conference on Harmonization and Food and Drug Administration rules. The examination was performed on the HPLC framework outfitted with a utilizing Gemni C18, (5 µm) (250 mm x 4.6 mm), with of Buffer (20mM Ammonium Acetate in water, pH 3.5) and Methanol: Acetonitrile 40:10 (%V/V) 60: 40 v/v with at a stream pace of 1.0 mL/min, segment temperature 35°C, absolute run time was 10 min, infusion volume 10 µl, and discovery was performed at the frequency (λ) of 265 nm. The adjustment plot gave direct relationship over the fixation scope of Metformin Hydrochloride 20, 40, 100, 200, 400 and 500 µg/ml, and Gemigliptin 1, 2, 5, 10, 20 and 25 µg/ml, individually. The exactness of the proposed technique was dictated by recuperation considers and was viewed as Metformin Hydrochloride 99.0 % to 101.0 % and Gemigliptin 98.0 % to 100.0 %.The Limit of Detection were 50.56 and 14.21 µg/ml for Metformin Hydrochloride and Gemigliptin, individually and the Limit of Quantitation were 166.85 and 43.90 µg/ml for Metformin Hydrochloride and Gemigliptin, respectively% Relative Standard Deviation of the assurance of accuracy was <2%. The consequences of vigor and arrangements strength studies were inside as far as possible too the principle elements of the created technique are low run time and maintenance season of around 2.9 min for Metformin Hydrochloride (Met) and 7.4 min for Gemigliptin [9]
5. Quality by plan (QbD) alludes to the accomplishment of specific unsurprising quality with wanted and foreordained determinations. The target of this review was to create and show an integratedmultivariate way to deal with create and measure the constituent convergences of glipizide (GPZ) drug in its unadulterated and tablet forms.The strategy was created utilizing Zorbax Extend C-18 (50mm × 4.6mm × 1.8 μm) segment with portable stage comprising of a combination of phosphate cushion of pH 3.5 and acetonitrile (60 : 40 v/v). The strategy satisfied approval standards and was demonstrated to be touchy, with cutoff points of discovery (LOD) and quantitation (LOQ) of 0.001 and 0.005 μgmL−1, individually. The rate relative standard deviations for heartiness and roughness were seen inside the scope of 0.1 and 0.99.Thecalibration chart was direct in the scope of 0.005–300 μgmL−1.The appropriateness of the technique was shown by the examination of detailed medication and spiked pee tests. The proposed strategy can be utilized for routine examination in quality control research centers for its mass and figured item, and this is the principal UPLC technique revealed for the test of GPZ in mass, detailed structure and pee. [10]
6. An proficient and basic HPLC technique has been created and approved for the concurrent assurance of gliclazide and metformin hydrochloride in mass and was applied on showcased metformin and gliclazide items. The versatile stage utilized for the chromatographic runs comprised of 20 mM ammonium formate support (pH 3.5) and acetonitrile (45:55, v/v) The partition was accomplished on an Alltima CN (250 mm _ 4.6 mm x5m) section utilizing isocratic mode. Medication tops were very much isolated and were identified by an UV locator at 227 nm. The strategy was direct at the focus range 1.25e150 mg/ml for gliclazide and 2.5e150 mg/ml for metformin separately. The strategy has been approved by ICH rules as for framework appropriateness, explicitness, accuracy, exactness and vigor. Metformin breaking point of location (LOD) and cutoff of evaluation (LOQ) were 0.8 mg/ml and 2.45 mg/ml separately while LOD and LOQ for

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 210-218 www.ijprajournal.com ISSN: 2249-7781

gliclazide were 0.97 mg/ml and 2.95 mg/ml individually.[11]

7. A fluid chromatographic strategy has been set up for the detachment of metformin, glipizide, gliclazide, glibenclamide and glimepiride utilizing trial plan. The primary aim of this strategy is to advance appropriate chromatographic conditions for the legitimate elution of the medication atoms with insignificant examination time. The connection between the individual and consolidated impact of basic cycle boundaries and chromatographic proficiency was clarified and was accomplished with the guide of trial plan approach. Waters Sunfire C18 type section (150×4.6 mm, 5 µm molecule size) was utilized and 0.1 % acidic corrosive in water: acetonitrile blend was taken on as versatile stage (stream rate: 0.469 ml/min) for the detachment of analytes. The created strategy was approved and has been stretched out for the examine of showcased details. [12]
8. The created strategy brought about elution of Metformin hydrochloride at 2.45 min and Nateglinide at 4.21 min. The alignment bends were straight (r^2=0.999) in the fixation scope of 60-140 µg/ml and 14.4-33.2 µg/ml for Metformin hydrochloride and Nateglinide separately. The rate recuperations were viewed as 99.59-101.36 for Metformin hydrochloride and 98.43-101.38 for Nateglinide. The LOD was viewed as 2.18 µg/ml and 1.55 µg/ml for Metformin hydrochloride and Nateglinide separately. LOQ was viewed as 8.52µg/ml and 4.69µg/ml for Metformin hydrochloride and Nateglinide separately. [13]
9. Metformin HCl was eluted at 2.170 min and ertugliflozin pidolate at 2.929 min with a run season of 5.0 min. Linearity of the created technique was seen in the fixation scope of 0.9375–5.625 µg/ml for ertugliflozin pidolate and 62.5–375 µg/ml for metformin HCl with a relationship coefficient of 0.999 for both the medications. LOD for ertugliflozin pidolate and metformin HCl were 0.025 µg/ml and 0.87 µg/ml individually. LOQ for ertugliflozin pidolate and metformin HCl were 0.076 µg/ml and 2.63 µg/ml. [14]
10. A basic, exact and precise elite presentation fluid chromatography (HPLC) strategy was created for synchronous quantitative assurance of rosiglitazone maleate and glimepiride in unadulterated structures and in drug plan. The division was accomplished by C18 section utilizing methanol:20 mM ammonium dihydrogen phosphate [78:22 (v/v); pH 3.85] as portable stage at a stream pace of 1 mL/min and recognition at 240 nm. Division was finished in under 10 min. Linearity, exactness and accuracy were viewed as OK over the reaches 0.8–4.0 µg/mL for rosiglitazone maleate and 0.4–2.0 µg/mL for glimepiride. This technique was viewed as explicit, reproducible, exact and precise. Because of its effortlessness and exactness the strategy is especially reasonable for routine drug quality control. [15]
11. A straightforward, particular and exact Stability showing RP-HPLC technique was created for the synchronous assessment of Metformin Hydrochloride, Pioglitazone Hydrochloride and Glibenclamide in the Bulk and Pharmaceutical Dosage Forms utilizing glimepiride as an inner norm. The chromatographic partition of the three medications was accomplished on an opposite stage Inertsil-ODS, C18, 100X 4.6 mm, 5µm segment utilizing 0.1 M Ammonium acetic acid derivation cradle (pH 4.5adjusted by utilizing formic corrosive) and Acetonitrile in the proportion of 45:55 v/v with stream pace of 0.8 ml/min with infusion volume 20 µL and the recognition was done at 254 nm. The maintenance season of metformin hydrochloride, pioglitazone hydrochloride and glibenclamide and glimepiride were viewed as 1.1, 4.5, 5.9, 6.5min individually. The medication items were exposed to pressure states of acidic, soluble, oxidation, UV and Thermal conditions. The debasement items were very much settled from Metformin Hydrochloride, Pioglitazone Hydrochloride and Glibenclamide tops, subsequently showing the soundness demonstrating nature of the technique. The straight relapse investigation information for the alignment plots showed great direct relationship in the fixation scope of 62.5-375.00 µg/ml for metformin hydrochloride, 3.75-22.5 µg/ml for pioglitazone hydrochloride and 1.25-7.50 µg/ml for glibenclamide. The created strategy was effectively approved in agreement to ICH rules. Consequently, this strategy can be advantageously embraced for the standard investigation in quality control research facilities. [16]

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 210-218 www.ijprajournal.com ISSN: 2249-7781

12. Glimepiride is an oral enemy of diabetic medication, which is for the most part utilized in the treatment of Type 2 diabetes mellitus. It acts by animating insulin discharges from the beta cells of pancreas and is likewise known to improve the fringe insulin affectability in this way diminishing insulin obstruction. This article analyzes distributed insightful strategies that are accounted for so far for the assurance of glimepiride in drug details and organic examples. They incorporate different procedures like spectrophotometry, electrochemical strategies, slender electrophoresis, superior execution fluid chromatography, micellarelectro motor fine chromatography(MECC) with diode-cluster discovery (DAD), fluid chromatography-electrospray ionization-pair mass spectroscopy (LC-ESI-MS), fluid chromatography-mass spectroscopy (LC-MS) and dainty layer chromatography (TLC).[17]
13. A new, simple, precise, accurate and reproducible RP-HPLC method for Simultaneous estimation of bulk and pharmaceutical formulations. Separation of Metformin and Linagliptin was successfully achieve dona THERMO, C18, 250cmx4.6mm, 5µm or equivalent in an isocratic mode utilizing KH2PO4: Methanol (65:35) at a flow rate of 1.0mL/min and eluate was monitored at 226nm, with a retention time of 3.132 and 3.728 minutes for Metformin and Linagliptin respectively. The method was validated and found to be linear in the drug concentration range of 50µg/ml to150 µg/ml for Metformin and 50µg/ml to150 µg/ml for Linagliptin. The values of the correlation coefficient were found to 0.999for Metformin and 1 for Linagliptin respectively. The LOD and LOQ for Metformin were found to be 1.909 and 6.362 respectively. The LOD and LOQ for Linagliptin were found to be 0.0349 and 0.1163 respectively. This method was found to be good percentage recovery for Metformin and Linagliptin were found to be 100 and 100 respectively indicates that the proposed method is highly accurate. The method was extensively validated according to ICH guidelines for Linearity, Accuracy, Precision, Specificity and Robustness.[18]
14. A reverse-phase high performance liquid chromatographic method for the estimation of Saxagliptin. The mobile phase consists of buffer (0.02M sodium dihydrogen phosphate, pH-3 adjusted with ortho phosphoric acid): methanol: acetonitrile in the ration of 45:20:35 v/v/v delivered at a flow rate of 1.0 ml/min and wavelength of detection at 220 nm. The retention time of Saxagliptin was 8.20 min. [19]
15. A RP-HPLC method for the simultaneous estimation of Metformin and Saxagliptin. The method was carried out on C18 column (5 µm, 25 cm X 4.6 mm, i.d.) using phosphate buffer (pH 5.0): acetonitrile: methanol in the ratio of 75:15:10 respectively as a mobile phase at a flow rate of 1.5 ml/min. The wavelength for Metformin and Saxagliptin at 225 nm was found to be appropriate. The retention time of Metformin and Saxagliptin was found to be 5.65 min and 6.20 min, respectively. [20]
16. A high performance liquid chromatographic method for the analysis of Saxagliptin and Pioglitazone. Chromatographic separation achieved isocratically on a C18 column (Use Inertsil C18, 5 µm, 150 mm X 4.6 mm) utilizing a mobile phase of acetonitrile: phosphate buffer (60:40, v/v, pH 7.0) at a flow rate of 0.8 ml/min with UV detection at 260 nm. The retention time of Saxagliptin and Pioglitazone was 2.48 min and 4.45 min, respectively. [21]
17. A reverse-phase high performance liquid chromatographic method for the determination of Metformin HCl (MFH) and Saxagliptin (SGP). The separation was eluted on a Zodiac C18 column (150 mm X 4.6 mm; 5 µm) using a mobile phase mixture of phosphate buffer pH 6.8 and acetonitrile in the ratio of 94:6 v/v at a flow rate of 1 ml/min. The detection was made at 248 nm. The retention times were 1.6 min for (MFH) and 4.1 min for (SGP). [22]
18. A RP-HPLC method for the simultaneous estimation of Saxagliptin and Metformin using C18 column (Phenominex, 250 X 4.6 mm, 5 µm) in isocratic mode. The mobile phase consisted of 0.02M potassium dihydrogen phosphate (KH2PO4): acetonitrile: methanol in the ratio of 50:25:25 (v/v/v) at pH 4.3. The detection wavelength was carried out at 240 nm. [23]
19. A RP-HPLC method for the simultaneous estimation of Metformin hydrochloride (MET) and Saxagliptin (SGL). Chromatography was carried on Phenominex C18 (250 mm X 4.6 mm, 5 µm) column with mobile phase

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 210-218 www.ijprajournal.com ISSN: 2249-7781

comprising of phosphate buffer: acetonitrile in the ratio (60:40) v/v. The flow rate was adjusted to 0.7 ml/min with UV detection at 242 nm. The retention times of MET and SGL were found to be 1.7 min and 2.9 min, respectively. [24]

20. A reverse-phase high performance liquid chromatographic method (RP-HPLC) for the simultaneous analysis of Metformin and Saxagliptin. The method was achieved on Enable C18G (250 X 4.6 mm; 5 µm particle size) column using 0.05 M KH2PO4 buffer (pH 4.5): methanol: acetonitrile (60:20:20 % v/v/v) as a mobile phase at a flow rate of 0.6 ml/min and by employing UV detection at 220 nm wavelength. The retention time of Metformin and Saxagliptin were found to be 4.38 min and 6.92 min, respectively. ACK. [25]
21. RP-HPLC method for the simultaneous determination of Metformin and Saxagliptin. This method is based on RP-HPLC separation of the two drugs on the Inspire C18 column (250 mm X 4.6 mm, 5.0 µ); and mobile phase containing buffer: methanol in a ratio of 55:45 v/v at a flow rate of 1 ml/min, using UV detection at 208 nm.[26]
22. A reversed-phase HPLC method to measure simultaneously the amount of Metformin and Vildagliptin at single wavelength (258 nm). An isocratic elution performed on Water's C18 column with buffered mobile phase (0.1M dipotassium phosphate buffer (pH 7): acetonitrile in the ratio of 70:30 (v/v) with PDA detection at 258 nm. [27]
23. A reversed-phase liquid chromatography method for the determination of Vildagliptin (VLG). The separation was achieved on Xtera® waters C18 column (150 mm X 4.6 mm, 5 µm) using mobile phase consisting of a mixture of aqueous phase (1 ml of 25% ammonium hydroxide was dissolved in 100 ml of water for chromatography, pH of the solution was adjusted to the value of 9.5 using a 50% solution of phosphoric acid) and organic phase (methanol) in the ratio of 60:40 v/v at a flow rate of 1 ml/min. Detection was carried out at 210 nm. The retention time of Vildagliptin was found to be 6.3 min. [28]
24. A reverse-phase high performance liquid chromatography method for the simultaneous determination of Vildagliptin and Metformin. The determination was performed by the using of two phases one is stationary phase it's a Thermo Hypersil ODS C18 column having 250 X 4.6 mm, 5 µm, and another one is mobile phase containing 0.1M Potassium hydro phosphate and acetonitrile at the ratio (60:40%v/v). Adjust the pH: 7.0 by using ortho phosphoric acid. The flow rate was 1 ml/min and effluents were monitored at 263 nm. The retention time of Metformin and Vildagliptin was 2.1 min and 3.5 min, respectively. [29]
25. A RP-HPLC method for the simultaneous estimation of Metformin hydrochloride and Vildagliptin. Chromatography was carried on Dionex C18 (250 mm X 4.6 mm i.d, 5µm) column with mobile phase comprising of di potassium hydrogen phosphate (0.01M) buffer: water in the ratio 90:10 v/v. The flow rate was adjusted to 1.5 ml/min with UV detection at 215 nm. The retention times of Metformin hydrochloride, Vildagliptin were found to be 2.390 min and 4.601 min, respectively. [30]
26. A reverse-phase liquid chromatographic method for simultaneous determination of Vildagliptin and Metformin in combination. The separation was carried out using a mobile phase consisting of 2mM phosphate buffer and acetonitrile with pH 3.5 adjusted with ortho phosphoric acid in the ratio of 70:30% v/v. The column used was Phenomenex C18, (250 mm X 4.6 mm i.d, 5 µm) with flow rate of 1 ml/min using PDA detection at 293 nm. The retention times of Vildagliptin and Metformin were found to be 2.1 min and 2.5 min, respectively. [31]
27. A RP-HPLC method for the simultaneous estimation of Vildagliptin (VIDA) and Metformin hydrochloride (MET). Chromatography was carried on Waters HPLC, Linchrocart C18 column (250 mm X 4.60 mm i.d, 5 µm) with mobile phase comprising of 0.05M KH2PO4: acetonitrile (70:30 v/v pH 3.5 with orthophosphoric acid). The flow rate was adjusted to 1.0 ml/min with UV detection at 215 nm. The retention time of VIDA and MET were found to be 6.64 min and 5.18 min, respectively. [32]
28. A HPLC method for the simultaneous determination of Metformin and Vildagliptin. The method was carried out using Sunfire BDS C8 column (250 mm X 4.6 mm, 5 µm) and mobile phase comprised of disodium hydrogen phosphate pH 7.0 ± 0.05 as buffer and

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 210-218 www.ijprajournal.com ISSN: 2249-7781

acetonitrile in the ratio of 60:40 v/v. The flow rate was 1.0 ml/min and the effluent was monitored at 263 nm. The retention times of Metformin and Vildagliptin were 2.07 min and 3.52 min, respectively. [33]

29. A reversed-phase high performance liquid chromatographic method for the simultaneous estimation of Vildagliptin and Metformin HCl. The proposed method is based on the separation of the two drugs in reversed-phase mode using Zodiac column (250 X 4.6 mm I.D., 5 µm particle size). The optimized mobile phase was disodium hydrogen phosphate buffer (pH 3.5): methanol in the ratio 73.5:26.5 v/v. The flow rate was at 1.0 ml/min and UV detection at 200 nm. The retention times were 2.490 min and 4.243 min for Metformin HCl and Vildagliptin, respectively.[34]
30. A RP-HPLC method for the simultaneous determination of Vildagliptin and Metformin. The proposed method is based on the separation of two drugs in the reversed phase mode using Waters C18 250 X 4.6 mm, 5 µ column maintained at a temperature of 450C. The optimum mobile phase consisted of 0.1M phosphate buffer (pH-7): acetonitrile (70:30), mobile phase flow rate of 1 ml/min and the effluents were monitored at 263 nm.[35]

III. CONCLUSION

There are extensive decision of insightful strategies were open for the examination of MET, EMP and LIN alone or in blend with different medications in drug and organic examples. The accessible information it was uncovered that HPLC strategy was extensively utilized for the assessment of MET, EMP and LIN in different grids like plasma and serum. HPLC MS/MS strategy is likewise suggested in the assurance of MET, EMP and LIN in natural examples in light of the fact that HPLC detachment capacity with MS affectability and selectivity permits the unambiguous distinguishing proof of MET, EMP and LIN and its metabolites. HPLC with UV location is material on account of examination of MET, EMP and LIN in drugs which give us practical exact strategy when contrast and more development procedures. Different bioanalytical strategy advancement and approval has been acted to concentrate on the bioavailability and bioequivalence of the medication which would help the physicists/examinations to figure a balanced out drug.

REFERENCES

[1]. R. Shimizu, K. Ishii,N. Tsumagari,M. Tanigawa, andM.Matsumoto. Determination of optical isomers in diltiazem hydrochloride by high-performance liquid chromatography. J. Chromatogr A. 253: 101–108 (1982).

[2]. R. Shimizu, T. Kakimoto, K. Ishii, Y. Fujimoto, H. Kishi and N. Tsumagari. New derivatization reagent for the resolution of optical isomers in diltiazem hydrochloride by high-performance liquid chromatography. J. Chromatogr A. 357: 119–125 (1986).

[3]. K. Ishii, K. Minato, N. Nishimura, T. Miyamoto, and T. Sato. Direct chromatographic resolution of four optical isomers of diltiazem hydrochloride on a Chiralcel OF column. J. Chromatogr. A 686(1): 93–100 (1994).

[4]. B.S.Madhira,D.M. Vaibhav, A.S.Dimal, K.B. Kashyap, S.M. Rajendra, G. Madhira, J.P. Binita. Estimation of pioglitazone hydrochloride and metformin hydrochloride in tablets by derivative spectrophotometry and liquid chromatographic methods. J. AOAC Internat.88(4): 1167–1172 (2005).

[5]. T. Radhakrishna, R.D. Sreenivas, and R.G. Om. Determination of pioglitazone hydrochloride in bulk and pharmaceutical formulations by HPLC and MEKC methods. J. Pharmaceut. Biomed. Anal. 29(4): 593–607 (2002).

[6]. Mahmoud M. Sebaiy, Sobhy M. El-Adl, Mohamed M. Baraka and Amira A. Hassan, Rapid RP-HPLC Method for Simultaneous Estimation of Metformin, Pioglitazone, and Glimepiride in Human Plasma, Acta Chromatographica 32(2020)1, 16–21

[7]. Najma Sultana1, M. Saeed Arayne2, Nighat Shafi1, Farhan Ahmed Siddiqui2,*, and Azhar Hussain, Development and Validation of New Assay Method for the Simultaneous Analysis of Diltiazem, Metformin, Pioglitazone and Rosiglitazone by RP-HPLC and its Applications in Pharmaceuticals and Human Serum, Journal of Chromatographic Science, Vol. 49, November/December 2011

[8]. P. Venkateswara Rao , A. Lakshmana Rao, and S.V.U.M Prasad, A new stability indicating RP-HPLC method for simultaneous estimation of ertugliflozin and sitagliptin in bulk and pharmaceutical

dosage form its validation as per ich guidelines, IAJPS 2018, 05 (04), 2616-2627

[9]. Suleman S. Khoja and Laxman J. Patel, Development and Validation of New RP-HPLC Method for the Estimation of Antidiabetic Drugs Metformin Hydrochloride and Gemigliptin in Combined Pharmaceutical Dosage Form, Journal of Pharmaceutical Research International 33(30B): 149-160, 2021

[10]. Cijo M. Xavier, Kanakapura Basavaiah, K. B. Vinay, and N. Swamy, Quality by Design Approach for the Development and Validation of Glipizide, an Antidiabetic Drug, by RP-UPLC with Application to Formulated Forms and Urine, ISRN Chromatography Volume 2013, Article ID 738397, 10 pages

[11]. Ahmed Gedawy , Hani Al-Salami , Crispin R. Dass, Development and validation of a new analytical HPLC method for simultaneous determination of the antidiabetic drugs, metformin and gliclazide, j ournal of food and drug analysis 27 (2019) 315-3 22

[12]. V. Bukkapatnam, Mukthinuthalapati Mathrusri Annapurna and K. C. Routhu, Experimental Design Methodology for Simultaneous Determination of Anti-Diabetic Drugs by Reverse Phase Liquid Chromatographic Method, Indian J Pharm Sci 2021;83(3):523-534

[13]. Prasanthi chengalva, Angala Parameswari S., Aruna G., Development and validation of RP-HPLC method for metformin hydrochloride and Nateglinide in bulk and combined dosage form,_Int J Pharm Pharm Sci, Vol 8, Issue 4, 267-271

[14]. K. Sravana Kumari and Sailaja Bandhakavi, Development and validation of stabilityindicating RP-HPLC method for the simultaneous determination of ertugliflozin pidolate and metformin hydrochloride in bulk and tablets, Future Journal of Pharmaceutical Sciences (2020) 6:66

[15]. Shweta shashikat Havele and Sunil Rajaram Dhaneshwar, Development and validation of LC method for the simultaneous estimation of rosiglitazone maleate and glimepiride in pharmaceutical dosage form, Malaysian Journal of Pharmaceutical Sciences Vol. 10, No. 1, 11–21 (2012)

[16]. Sai Thanuja V, Chandan R S, Anandkumar R Tengli, Gurupadayya B M, Prathyusha W, Stability Indicating RP-HPLC Method for the Simultaneous Estimation of Metformin Hydrochloride, Pioglitazone Hydrochloride and Glibenclamide in Bulk and Pharmaceutical Dosage Forms, IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) p-ISSN:2319-7676. Volume 9, Issue 1, Ver. IV (Jan. 2014), PP 124-133

[17]. Shobha Rani G, Lohita M, Jaya Preethi P, Madhavi R, Sunisitha B, Mounika D, Glimepiride: A Review of Analytical Methods, Asian J. Pharm. Ana. 2014; Vol. 4: Issue 4, Pg 178-182

[18]. S. Srinivasa Rao, M. Chandra Shekar, N. Nagaprasanna and T. Supriya, Analytical Method Development And Validation Of Antidiabetic Drugs (Metformin And Linagliptin) In Tablet Dosage Form By Using RP- HPLC Method, WJPLS, 2019, Vol. 5, Issue 8, 113-120

[19]. Srikanth Inturi, Ravikanth Inturi and Isreal kumar Tagaram. Validated Novel LC Determination of Saxagliptin in Pure Bulk and Pharmaceutical Dosage Forms. International Journal of Pharmaceutical Research and Development. 2011; 3(8): 45-52.

[20]. R. Pravin Cumar, M. Vasudevan and Deecaraman. A Validated RP-HPLC Method for Simultaneous Estimation of Metformin and Saxagliptin in Tablets. Rasayan Journal of Chemistry. 2012; 5(2): 137-141.

[21]. M. Sarat, P. Muralikrishna and C. Rambabu. RP-HPLC Method for Simultaneous Estimation of Sexagliptin and Pioglitazone in Tablets. International Research Journal of Pharmacy. 2012; 3(5): 399-402.

[22]. Patil Prafulla Prakash et al. A New RP-HPLC Method for Determination of Metformine HCl and Saxagliptin in Tablet Dosage Form. International Journal of Pharmacy and Biological Sciences. 2012; 2(4): 161-167.

[23]. Nyola Narendra and Govindasamy Jeyabalan. Simultaneous Estimation of Saxagliptin and Metformin Hydrochloride in Active Pharmaceutical Ingredient by RP-HPLC. Asian Journal of Pharmaceutical

Research and Health Care. 2012; 4(3): 70-77.

[24]. B. Thangabalan, P. Srisowmya and S. Manohar Babu. Method Development for the Simultaneous Estimation of Saxagliptin and Metformin in Tablet Dosage Form by RP-HPLC Method. International Journal of Pharmacy and Analytical Reaseach. 2014; 3(4): 363-369.

[25]. P.B.N. Prasad, K. Satyanarayana and G. Krishnamohan. Development and Validation of a Method for Simultaneous Determination of Metformin and Saxagliptin in a Formulation by RP-HPLC. American Journal of Analytical Chemistry. 2015; 6: 841- 850.

[26]. A.C.K. Prasanna and Kanuri Priyanka. Method Development and Validation of Simultaneous Determination of Metformin and Saxagliptin in Pharmaceutical Dosage Form by RP-HPLC. International Journal of Pharmaceutical Chemical and Biological Sciences. 2015; 5(1): 381-387.

[27]. B. Mohammed Ishaq, Dr. K.Vanitha Prakash and Dr. G.Krishna Mohan. RP-HPLC Method for Simultaneous Estimation of Metformin and Vildagliptin in Bulk and its Tablet Formulation. Journal of Global Trends in Pharmaceutical Sciences. 2012; 3(3): 747-754.

[28]. Aparajita Malakar, Bishwajit Bokshi and DilrubaNasrin. Development and Validation of RP-HPLC Method for Estimation of Vildagliptin from Tablet Dosage Form. International Journal of Pharmaceutical and Life Sciences. 2012; 1(1): 1-8.

[29]. Subhakar Nandipati, V. Krishna Reddy and T. Ravindranadh Reddy. Development and Validation of RP-HPLC Method for Simultaneous Determination of Vildagliptin and Metformin in Bulk and Formulation Dosage Form. International Research Journal of Pharmaceutical and Applied Sciences. 2012; 2(3): 44-50.

[30]. B. Santhosha, A. Ravindranath and C. Sundari. Validated Method for the Simultaneous Estimation of Metformin Hydrochloride and Vildagliptin by RP-HPLC in Bulk and the Pharmaceutical Dosage Form. International Research Journal of Pharmaceutical and Applied Sciences. 2012; 2(3): 22-28.

[31]. K. Pushpalatha and D. Ramachandran. Method Development and Validation for the Simultaneous Estimation of Vildagliptin and Metformin in Tablet Dosage Form by RP-HPLC. International Journal of Pharmacy and Pharmaceutical Sciences. 2013; 5(1): 459-463.

[32]. B. Shrikrishna Baokar, V. Sugandha Mulgund and S. Nisharani Ranpise. Development and Validation of RP-HPLC Method for Simultaneous Estimation of Vildagliptin and Metformin. Research Journal of Pharmaceutical Dosage Forms and Technology. 2013; 5(2): 95-98.

[33]. P.S.R.CH.N.P. Varme D, A. Lakshmana Rao and S.C. Dinda. Simultaneous Determination of Metformin and Vildagliptin in Solid Dosage Form by Stability Indicating RP-HPLC Method. International Research Journal of Pharmacy. 2013; 4(1): 122- 128.

[34]. Gattu Madhava Prathap, M. Muthukumaran and B. Krishnamoorthy. Development and Validation of Simultaneously Estimation of Vildagliptin and Metformin Hydrochloride by RP-HPLC in Bulk and Oral Dosage Form. International Journal of Advanced Pharmaceutical Genuine Research. 2014; 2(1): 24-33.

[35]. K. Hanumantha Rao, A. Lakshmana Rao and K.B. Chandra Sekhar. Development and Validation of HPLC Method for the Estimation of Vildagliptin in Pharmaceutical Dosage Form. International Journal of Pharmaceutical Chemical and Biological Sciences. 2014; 4(2): 361-366.